<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="230">
  <!-- This xml conforms to:  http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>Information obtained from ClinicalTrials.gov on October 20, 2011</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01219816</url>
  </required_header>
  <id_info>
    <org_study_id>BRD 10/05-O</org_study_id>
    <nct_id>NCT01219816</nct_id>
  </id_info>
  <brief_title>Multi-centric Study</brief_title>
  <acronym>CHEPRALL</acronym>
  <official_title>Phase II, Multicenter, Open Label, Prospective to Evaluate Efficacy and Tolerance of a Chemoimmunotherapy With HyperCVAD or Vincristine/Dexamethasone Plus the Anti-CD22 Monovlonal Antobody Epratuzumab for the Treatment of Adult Relapsed/Refractory CD22+ B-Acute Lymphoblastic Leukaemia Patients : CHEPRALL Study, a GRAALL Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <authority>France : AFSSAPS - French Health Prducts Safety Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with relapsed/refractory adult acute lymphoblastic leukemia (ALL)have a very dismal
      prognosis. In this case, allogeneic transplantation is the only curative treatment when
      patient have obtained a second complete remission (CR. In France, in patients younger than
      60 years old,the HyperCVAD regimen used by the MDAnderson in Houston is generally applied.
      In older patients (&gt;=60 years)or young patients &lt;= 60 years no eligible for intense
      chemotherapy, a combination of vincristine + Dexamethasone is generally chosen in order to
      avoid too much toxicity but the result is worse in term of CR.

      More than 90% of ALL with a B phenotype (2/3 of cases in adults)express the surface antigen
      CD22 on leukemic blasts which thus represents an interesting target for therapy. Epratuzumab
      is a humanized anti-CD22 antibody produced by Immunomedics, Inc, Morris Plain (New Jersey,
      USA). Epratuzumab has already shown efficacy in lymphoma patients. Only one study, including
      15 children, has been published so far reporting the efficacy and the toxicity of
      Epratuzumab in the setting of ALL in monotherapy, one can observe 8 stable disease, 3
      progressions and 4 partial responses. When combining chemotherapy and Epratuzumab, 9CR were
      observed with acceptable toxicity. Tolerance was acceptable.

      The French GRAALL group proposes to test an age-adapted combination of chemotherapy +
      Epratuzumab, in refractory/relapses CD22+ B ALL patients in order to improve their
      prognosis, in term of CR, survival and of number of patients eligible for allograft.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2010</start_date>
  <primary_completion_date type="Anticipated">January 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation:  Non-Randomized, Endpoint Classification:  Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Treatment</study_design>
  <primary_outcome>
    <measure>complete response rate (CR and CRp)</measure>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)(CR, CRp and PR)</measure>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD22 expression after Epratuzumab</measure>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerance of Epratuzumab in combination with chemotherapy</measure>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>B ALL</condition>
  <condition>CD22+ Expression</condition>
  <condition>Refractory B-ALL</condition>
  <arm_group>
    <arm_group_label>Patients under 60 years</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hyper CVAD regimen + Epratuzumab (Cyclophosphamide Vincristine Doxorubicin Dexamethasone)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients older than 60 years or &lt; =60 years</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vincristine + Aracytine + Dexamethasone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epratuzumab</intervention_name>
    <description>Combination of chemotherapy + Epratuzumab</description>
    <arm_group_label>Patients under 60 years</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epratuzumab</intervention_name>
    <description>Vincristine + Dexamethasone + Epratuzumab</description>
    <arm_group_label>Patients older than 60 years or &lt; =60 years</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;= 18 years

          -  B-ALL (OMs) with &gt;= 20 % of blasts in bone marrow

          -  CD22+ expression &gt;= 30% of the blast population

          -  Refractory B-ALL defined by treatment failure after 2 successive courses of induction
             therapy or relapse &lt; 6 months after first CR

          -  First relapse of B-ALL

          -  Second relapse or beyond

          -  Performance status 0-2

          -  Creatinine clearance &gt;= 50 ml/min (Cockroft formula)

          -  Serum bilirubine &lt;= 30 µmom/l

          -  Written informed consent

        Exclusion Criteria:

          -  T-ALL

          -  Meningeal involvement

          -  CD22 expression on tumor cells or &lt; 30%

          -  HIV positive

          -  Active Hepatitis B or C

          -  Left ventricular ejection fraction &lt; 50% in patients &lt;60 years

          -  Contra-indication to Epratuzumab

          -  Previous or concurrent second malignancy except for adequately treated basal cell
             carcinoma of the skin, curatively treated in situ carcinoma of the cervix, curatively
             treated solid cancer, with no evidence of disease for at least 5 years

          -  Any psychological, familial, sociological or geographical condition potentially
             hampering compliance with the study protocol and follow-up schedule

          -  Participation at the same time in another study in which investigational drugs are
             used

          -  Absence of written informed consent
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrice CHEVALLIER, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nantes University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patrice CHEVALLIER, MD,</last_name>
    <phone>+33(0)240083271</phone>
    <email>patrice.chevallier@chu-nantes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Angers University Hospital</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Mathilde HUNAULT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Oumedaly REMAN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HEnri Mondor Hospital</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Sébastien MAURY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Edouard Herriot Hospital</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Xavier THOMAS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmette</name>
      <address>
        <city>Marseille</city>
        <zip>13373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Anne ETIENNE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nantes University Hospital</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrice CHEVALLIER</last_name>
      <phone>+33 2 40 08 32 71</phone>
      <email>patrice.chevallier@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Patrice CHEVALLIER, DR</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Françoise ISNARD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Louis Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Herve DOMBRET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Haut-Leveque Hospital</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Thibaut LEGUAY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Purpan Hospital</name>
      <address>
        <city>Toulouse</city>
        <zip>37509</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Françoise HUGUET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <lastchanged_date>October 18, 2011</lastchanged_date>
  <firstreceived_date>October 12, 2010</firstreceived_date>
  <responsible_party>
    <name_title>Dr Patrice CHEVALLIER, principal investigator</name_title>
    <organization>University Hospital</organization>
  </responsible_party>
  <keyword>efficacy of Chemo-immunotherapy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burkitt Lymphoma</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
</clinical_study>
